Optimizing Allogeneic Cell Therapy Manufacturing with Atara Biotherapeutics

We've got a new episode of Data in Biotech for you!

This week, we’re joined by Amy Gamber, VP of Manufacturing at Atara Biotherapeutics, an allogeneic T-cell immunotherapy company that is developing off-the-shelf treatments to help achieve faster patient outcomes.

As a treatment at the cutting edge of options available for cancer and autoimmune disease, Ross digs into how Atara is able to deliver personalized medicine to the patient within a three-day window.

Amy is clear-eyed about what works well in this field and what doesn’t.

She shares her insights into the complexity of developing this type of cell therapy and the subsequent production challenges of manufacturing at scale.

Ross and Amy also cover the manufacturing process, corresponding data problems Amy encounters on a day-to-day basis in her role as VP of Manufacturing, and the strategies she employs to overcome them.

Enjoy the interview wherever you get your podcasts. Links to Apple and Spotify in the comments.